Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-09-14

Clinical Trial Update: Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV [Phase 3]

View source ↗

Summary

Phase III trial evaluating the combination of daclatasvir and sofosbuvir for genotype 3 chronic hepatitis C completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Daklinza (Daclatasvir)
  • Sovaldi (Sofosbuvir)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2015-09-14